advanced clinical education foundation of the new york state society for clinical social work, inc.

one commerce plaza
99 washington avenue #805
albany, new york 12210

NYS Entity Status
ACTIVE

NYS Filing Date
JULY 15, 2014

NYS DOS ID#
4606372

County
NEW YORK

Jurisdiction
NEW YORK

Registered Agent
NONE

NYS Entity Type
DOMESTIC NOT-FOR-PROFIT CORPORATION

Name History
2014 - ADVANCED CLINICAL EDUCATION FOUNDATION OF THE NEW YORK STATE SOCIETY FOR CLINICAL SOCIAL WORK, INC.









Buffer



submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • AROUND THE WEB

  • Gates Foundation Awards $12.6 Million for Polio Vaccine Research
    By webmaster@philanthropynewsdigest.org (Matt Sinclair) - Sunday Jun 11, 2017

    The three-year grant to Korean chemical company LG Chem will be used to advance clinical trials on a new inactivated polio vaccine....

    Source: Philanthropy News Digest (PND)
  • Cleveland Clinic Receives $10 Million for Expansion of Eye Institute
    By webmaster@philanthropynewsdigest.org (Mitch Nauffts) - Monday Jun 5, 2017

    The gift from the Timken Foundation of Canton will support an expansion of the Cole Eye Institute and the creation of the Louise Timken Ophthalmic Education Center....

    Source: Philanthropy News Digest (PND)
  • Bio Roundup: ASCO Digested, Juliet Unveiled, PTC Slated & More
    By Alex Lash - Friday Jun 9, 2017

    The New York Times Magazine wrote a few weeks ago about the extraordinary metabolic changes in a python after it gulps down a 50,000 calorie meal. The biomedical world was like a postprandial python this week; after extending its maw around the supersized meal of news and data from the American Society for Clinical Oncology […]

    Source: Xconomy New York
  • FDA Halts Merck’s Multiple Myeloma Trials After Patient Deaths
    By Frank Vinluan - Wednesday Jul 5, 2017

    Nearly a month after Merck paused enrollment in three clinical trials in multiple myeloma to gather more information about patient deaths, the FDA has now put a stop to those studies altogether. Merck (NYSE: MRK) said Wednesday that the FDA has placed a complete hold on two Phase 3 trials testing its immunotherapy drug pembrolizumab […]

    Source: Xconomy New York
  • Precision Steps: Can Loxo Drug Help Broaden Use of Cancer DNA Tests?
    By Ben Fidler - Saturday Jun 3, 2017

    When the FDA last week approved Merck’s cancer drug pembrolizuamb (Keytruda) for tumors with a specific genetic signature, regardless of what body part they originated in, it was a watershed moment for oncology and a victory for the concept of precision medicine. But Merck isn’t alone; others are following suit with similar plans, and their […]

    Source: Xconomy New York
  • Teva Seeks to Keep Pace in Migraine Drug Race With Trial Results
    By Frank Vinluan - Wednesday May 31, 2017

    An experimental Teva Pharmaceutical migraine drug has met the main goals of a late-stage clinical trial, keeping the drugmaker in the race to bring to the market a product that prevents migraine headaches instead of treating them after they start. Teva (NYSE: TEVA) reported Wednesday that its drug fremanezumab reduced the number of days during […]

    Source: Xconomy New York
advanced clinical education foundation of the new york state society for clinical social work inc albany ny